Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalized, physiotherapist-guided exercise programs in juvenile ıdiopathic arthritis: home-based vs. ımmersive virtual reality (JiaFitXR).

Rheumatology (Oxford, England)·2026
Same author

A giant coronary aneurysm posing as a cardiac mass: The stepwise diagnosis, medical and surgical management of Behçet disease in an adolescent.

Turk gogus kalp damar cerrahisi dergisi·2026
Same author

Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Tumor necrosis factor inhibitor-related autoimmune disorders in pediatric rheumatology practice: a multicenter nationwide study.

Pediatric rheumatology online journal·2026
Same author

A multicentre study for clinical phenotype prediction in juvenile dermatomyositis: categorical principal component analysis-based hierarchical clustering.

Reumatologia·2026
Same author

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026

Related Experiment Video

Updated: May 25, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Factor VII deficiency: a single-center experience.

Zafer Salcioglu1, Arzu Akcay, Hulya Sayilan Sen

  • 1Bakirkoy Children's and Maternity Education and Research Hospital, Istanbul, Turkey. zafersalcioglu@yahoo.com

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|February 14, 2012
PubMed
Summary

Congenital factor VII deficiency, a common rare bleeding disorder, affects children and adolescents. Recombinant activated factor VII (rFVIIa) effectively treated bleeding episodes and provided prophylaxis without adverse events.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Related Experiment Videos

Last Updated: May 25, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Area of Science:

  • Hematology
  • Genetics
  • Pediatrics

Background:

  • Congenital factor VII deficiency is the most prevalent rare inherited coagulation disorder.
  • This condition necessitates understanding its clinical spectrum and management strategies.

Purpose of the Study:

  • To retrospectively evaluate clinical characteristics, symptoms, and treatment outcomes in 73 patients with factor VII deficiency.
  • To assess the safety and efficacy of recombinant activated factor VII (rFVIIa) in managing bleeding episodes and prophylaxis.

Main Methods:

  • Retrospective analysis of 73 patients (2 months–19 years) diagnosed with factor VII deficiency.
  • Review of clinical symptoms, bleeding episodes, and treatment records, including rFVIIa use.
  • Genotyping performed in a subset of patients.

Main Results:

  • 42.5% of patients were asymptomatic; symptomatic cases ranged from mild to severe.
  • Common symptoms included epistaxis, petechiae/ecchymoses, easy bruising, and oral bleeding.
  • rFVIIa successfully treated 49 bleeding episodes in 8 patients and was used for prophylaxis in 2 patients with CNS bleeding.
  • No allergic reactions, thrombotic events, or antibody development were observed with rFVIIa treatment or prophylaxis.

Conclusions:

  • Factor VII deficiency presents with a variable clinical phenotype, with a significant proportion of patients remaining asymptomatic.
  • rFVIIa is a safe and effective therapeutic option for managing bleeding complications and for prophylaxis in patients with factor VII deficiency, including those with severe or recurrent bleeding.
  • Long-term monitoring did not reveal adverse events associated with rFVIIa therapy.